Ipamorelin 10 mg

About Ipamorelin

Ipamorelin acts at the receptor for ghrelin, a hormone that stimulates appetite.⁴¹⁰ According to FDA's 2024 review, it works mainly through ghrelin receptors on hypothalamic nerve cells that make GHRH, and also on growth hormone-producing pituitary cells.⁴ That is a different route from CJC-1295 No DAC, which mimics GHRH itself.⁴ Its 1998 discovery paper called it the first selective growth hormone secretagogue.³

Human studies gave it by IV infusion, apart from one nasal dose in a single volunteer.⁷⁸¹⁷ FDA's 2024 review found effectiveness data only for IV use after bowel surgery, where a phase 2 trial found no significant benefit.⁴⁸ This page lists ipamorelin for sale as a 10 mg research vial. What is Ipamorelin? covers the side effect data, published study doses and regulatory record.

Research highlights

• Rat pituitary cells (1998): growth hormone release with potency close to GHRP-6 (EC50 about 1.3 versus 2.2 nmol/L) and a maximal effect of 85% versus 100%.³
• Conscious swine (1998): GHRP-6 and GHRP-2 raised ACTH and cortisol, but ipamorelin stayed at GHRH levels even at more than 200 times its half-maximal growth hormone dose.³
• Healthy men (1999, eight at each of five doses): a 15-minute IV infusion caused one growth hormone pulse that peaked at 0.67 hours, and the drug's terminal half-life was about 2 hours.⁷
• Bowel surgery, 114 adults (phase 2, 2014): IV ipamorelin twice daily for up to 7 days did not significantly shorten the time to the first tolerated solid meal, a median 25.3 versus 32.6 hours on placebo (p = 0.15).⁸
• Rats after abdominal surgery (2009): one IV dose shortened the time to the first bowel movement, and repeated doses raised stool output, food intake and weight gain.¹⁰
• Adult female rats (1999): injections under the skin three times daily for 15 days sped bone lengthening from 42 to as much as 52 micrometers per day, without changing total IGF-I.¹¹
• Mice (2001): twice-daily injections raised body weight about 15% in 2 weeks and increased body fat, even in growth hormone-deficient mice.¹²

Regulatory status

No FDA-approved drug contains ipamorelin, and it has no USP or National Formulary monograph.⁴ Since September 29, 2023, FDA has placed ipamorelin acetate in Category 2 for outsourcing facilities (may present significant safety risks), citing possible immune reactions and serious adverse events, including death, in a published IV study.¹³ On October 29, 2024, FDA's compounding advisers voted 12 to 0, with 1 abstention, against adding each form of ipamorelin to the 503A bulks list.¹⁴

FDA warning letters dated August 24, 2026 to two online sellers called research-labeled tesamorelin and ipamorelin blends unapproved new drugs, because the sellers' websites showed they were meant for people.¹⁵¹⁶ WADA's 2026 list bans it at all times as a growth hormone secretagogue under S2.2.4.¹⁹ In an anti-doping study of one volunteer, a urine metabolite outlasted the parent drug.¹⁷

Handling and storage

FDA warns that peptides like ipamorelin can be very sensitive to formulation, processing and conditions such as pH, heat and concentration, which can make them clump (aggregate) or break down and lose activity.⁴ Water solubility depends on the salt form: sources cited by FDA give 5 mg/mL for ipamorelin acetate and 0.0032 mg/mL for the free base.⁴ At 5 mg/mL, 10 mg of the acetate needs at least 2 mL of water to dissolve fully.

The steps are in How to reconstitute a peptide vial, the reconstitution calculator does the concentration math, and How to store peptides covers storage before and after mixing.